There is currently no curative treatment for metastatic prostate cancer. Systemic therapy includes hormonal therapy, chemotherapy, immunotherapy and radiotherapy. While most patients will demonstrate initial clinical improvement, it is virtually inevitable that castration-resistant prostate cancer develops because of the inherent heterogeneity of prostate cancer and failure of current therapies to eradicate both androgen-dependant and androgen-independent components. The median time to development of castration-resistant prostate cancer is 9-30 months from the time of initiating hormonal treatment. Once this occurs, the median duration of survival is 24 months.
The ProstACT study, which commenced in October 2024, is a multinational, multicenter, prospective, randomised, controlled, open-label Phase 3 study to evaluate investigational radionuclide therapy, TLX591, in patients with PSMA-positive mCRPC, progressing on first-line androgen receptor pathway inhibition. This is a global study, in conjunction with Telix, and APC is the second site activated globally for Phase 3.
Radionuclide therapy (RNT) has been developed to localise therapy to specific tumour cells located in multiple organs to reduce or even eliminate damage to normal tissue. Central to this strategy has been the development of monoclonal antibodies (mAbs) that can act as a highly specific carrier of radioisotopes to selectively target these tumour cells and deliver a cytotoxic radiation dose. As such, a radiolabelled antibody is potentially more advantageous than using unlabelled therapeutic antibodies alone, by specifically targeting tumour cells as well as the adjacent tumour microenvironment to produce radiation-induced cytotoxicity.
Contact our research team at APC to find out how you can partner with us and get involved with our ground-breaking research.
